No Data
No Data
Express News | Sirnaomics Announces Completion of Ind-Enabling Studies of Safety and Efficacy for STP125G With Nhp Models, Targeting Apoc3 for Treatment of Cardiovascular Diseases
Shengnuo Medicine-B (02257. HK) announced the completion of the STP125G IND preparation stage study for the safety and efficacy of targeting APOC3 for the treatment of cardiovascular disease in non-human primate models.
On July 12, Gelunhui - July 12, 2024 - Sirnaomics Ltd. ("Company", stock code: 2257.HK, together with its subsidiaries, collectively referred to as "Group" or "Sirnaomics"), a leading biopharmaceutical company dedicated to exploring and developing RNAi therapies in the industry, announced today that the Group has completed the IND preparation study of siRNA therapeutic drug STP125G targeting lipoprotein C3 (ApoC3) based on its proprietary GalAhead mxRNA technology. Non-human primates
Sanofi(02257) has completed the IND preparation phase research for treatment drug STP125G in Hong Kong stock connect.
Jingu Finance News: Shengnuo Medicine (02257) announced that it has completed the IND preparation phase study of the siRNA therapeutic drug STP125G targeting the lipid carrier protein C3 (ApoC3). This is the second candidate drug based on its proprietary GalAhead mxRNA technology. The safety and efficacy results of non-human primate (NHP) studies strongly support applying for IND to the US FDA to initiate Phase I clinical studies of STP125G for cardiovascular disease indications. It is reported that lipid carrier protein C3 plays an important role in triglyceride metabolism, and has been a recent focus of research.
Stock market abnormality: Sanofi-Aventis-B (02257) rose more than 25% in the mid-trading session, and the second sequence of STP122G anticoagulant treatment clinical trials has been completed.
According to the Securities Times App, Shengnuo Medicine-B (02257) rose by more than 25% during the session, and as of the time of publication, it was up 17.32%, reporting HKD 5.08, with a turnover of HKD 40.5272 million. On the news front, Shengnuo Medicine announced that the second sequence of Phase I clinical trials for the GalNAc RNAi therapy drug STP122G for anticoagulation treatment has been successfully completed and mid-term data has been released. It is reported that this therapeutic product is a new type of anticoagulant therapy targeting eleven indicators. Safety data shows that dose-limiting toxicity or serious adverse events did not occur, while target silence dependent on dose was observed.
Sirnaomics Finds No Serious Adverse Events During Phase 1 Study for Coagulation Drug
Sirnaomics (HKG:2257) said there were no dose-limiting toxicities or serious adverse events for the second group of participants for its phase 1 study for its STP122G treatment, according to a Monday
Sirnaomics announced the successful completion of the second phase of Phase I clinical trial of STP122G, a GalNAc RNAi therapeutic drug for anticoagulant therapy, and released mid-term data.
On July 8, 2024, in Hong Kong, Maryland, USA, Germany City and Suzhou, Sirnaomics Ltd. (the "Company", along with its subsidiaries, collectively referred to as the "Group" or "Sirnaomics"; stock code: 2257), an industry-leading biopharmaceutical company focused on exploring and developing RNAi therapies, announced that the Phase I clinical trial of STP122G for anticoagulant therapy has successfully completed the second sequence and announced midterm data. This therapeutic product is a novel anticoagulant targeting Factor XI. Second sequence
No Data